Projects per year
Personal profile
Chinese Name
翟李翔
Research Interests
- Investigation of gut microbiota in the development of non-communicable diseases including functional gastrointestinal disorders, metabolic disorders and mental disorders.
- Investigation of Chinese medicine for the treatment of gut dysbiosis-induced metabolic disorders and functional gastrointestinal disorders.
- Metabolomics and lipidomics analysis of medicinal plants for pharmacological research and quality evaluation studies.
Biography
Dr. Lixiang Zhai completed his Bachelor of Science in Pharmacy in Chinese Medicine at Guangdong Pharmaceutical University in 2015, followed by a Ph.D. in Chinese Medicine from Hong Kong Baptist University in 2021. He underwent postdoctoral training at the Centre for Chinese Herbal Medicine Drug Development Limited (@InnoHK) from 2021 to 2022 and currently holds the position of Assistant Professor at the same institution.
Dr. Zhai's research is at the forefront of understanding the intricate interactions between the host and gut microbiota, which are pivotal in the development of functional bowel disorders, metabolic syndrome, and mental disorders. His focus extends to the clinical translation of Chinese medicine for treating gastrointestinal diseases, such as irritable bowel syndrome and inflammatory bowel disease, demonstrating a commitment to bridging traditional remedies with contemporary medical practices.
Having contributed to prestigious journals like Cell Host & Microbe, Nature Metabolism, Nature Communications, The Journal of Clinical Investigation, Phytomedicine, Phytotherapy Research and others, Dr. Zhai's publications underscore his significant impact on the fields of microbiota research and Chinese medicine. His work not only enriches the scientific community's understanding but also paves the way for novel therapeutic approaches in gastrointestinal healthcare.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Keywords
- RM Therapeutics. Pharmacology
- QP Physiology
- RS Pharmacy and materia medica
Fingerprint
Dive into the research topics where Lixiang ZHAI is active. Topic labels come from the works of this scholar.
- 1 Similar Scholars
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Improved Metabolic Network Reconstruction and Metabolite Profiles Prediction using Complete and Strain-Resolved Microbial Genomes
ZHANG, L. (PI), BIAN, Z. (CoPI), ZHAI, L. (CoPI), Li, S. (CoPI) & Li, J. (CoPI)
30/06/24 → 31/05/27
Project: Research project
-
肠道微生物芳香族氨基酸脱羧酶失调对肠易激综合征的腹痛症状和焦虑情绪的影响和机制研究
ZHAI, L. (PI), BIAN, Z. (CoI), WONG, H. L. X. (CoI), XU, S. (CoI) & BAO, G. (CoI)
1/01/24 → 31/12/26
Project: Research project
-
-
Pharmacodynamic and mechanism study of Lingzhi-Jianghuang Formula (LJF) extract on NAFLD in mice
BIAN, Z. (PI), LIN, C. (CoI), QIN, H. (CoI), LIU, Q. (CoI) & ZHAI, L. (CoI)
3/01/24 → 2/01/25
Project: Research project
-
Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome
Zhai, L., Xiao, H., Lin, C., Wong, H. L. X., Lam, Y. Y., Gong, M., Wu, G., Ning, Z., Huang, C., Zhang, Y., Yang, C., Luo, J., Zhang, L., Zhao, L., Zhang, C., Lau, J.Y.-N., Lu, A., Lau, L.-T., Jia, W. & Zhao, L. & 1 others, , 17 Aug 2023, In: Nature Communications. 14, 1, 14 p., 4986.Research output: Contribution to journal › Journal article › peer-review
Open Access44 Citations (Scopus) -
Ruminococcus gnavus plays a pathogenic role in diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis
Zhai, L., Huang, C., Ning, Z., Zhang, Y., Zhuang, M., Yang, W., Wang, X., Wang, J., Zhang, L., Xiao, H., Zhao, L., Asthana, P., Lam, Y. Y., Chow, C. F. W., Huang, J. D., Yuan, S., Chan, K. M., Yuan, C. S., Lau, J. Y. N. & Wong, H. L. X. & 1 others, , 11 Jan 2023, In: Cell Host and Microbe. 31, 1, p. 33-44.e5 12 p.Research output: Contribution to journal › Journal article › peer-review
80 Citations (Scopus) -
Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis
Guo, X., Asthana, P., Zhai, L., Cheng, K. W., Gurung, S., Huang, J., Wu, J., Zhang, Y., Mahato, A. K., Saarma, M., Ustav, M., Kwan, H. Y., Lyu, A., Chan, K. M., Xu, P., Bian, Z. X. & Wong, H. L. X., 3 Feb 2024, In: Nature Communications. 15, 1, 14 p., 1034.Research output: Contribution to journal › Journal article › peer-review
Open Access12 Citations (Scopus) -
Body weight regulation via MT1-MMP-mediated cleavage of GFRAL
Chow, C. F. W., Guo, X., Asthana, P., Zhang, S., Wong, S. K. K., Fallah, S., Che, S., Gurung, S., Wang, Z., Lee, K. B., Ge, X., Yuan, S., Xu, H., Ip, J. P. K., Jiang, Z., Zhai, L., Wu, J., Zhang, Y., Mahato, A. K. & Saarma, M. & 7 others, , 17 Feb 2022, In: Nature Metabolism. 4, 2, p. 203–212 10 p.Research output: Contribution to journal › Journal article › peer-review
25 Citations (Scopus) -
A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome
Zhao, L., Yang, W., Chen, Y., Huang, F., Lu, L., Lin, C., Huang, T., Ning, Z., Zhai, L., Zhong, L. L. D., Lam, W., Yang, Z., Zhang, X., Cheng, C., Han, L., Qiu, Q., Shang, X., Huang, R., Xiao, H. & Ren, Z. & 8 others, , 2 Jan 2020, In: Journal of Clinical Investigation. 130, 1, p. 438-450 13 p.Research output: Contribution to journal › Journal article › peer-review
Open Access124 Citations (Scopus)